TP53 and cancer: Tumors harboring TP53 mutations progress more rapidly and are more resistant to anticancer therapy than tumors harboring wild-type p5387, indicating that p53 mutants not only lose their tumor suppressor effects but also acquire new oncogenic activities that promote cancer progression.